Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 14, 2023

BUY
$4.45 - $6.17 $366,920 - $508,741
82,454 Added 8.73%
1,026,567 $6.17 Million
Q3 2022

Nov 14, 2022

SELL
$5.36 - $7.43 $305,520 - $423,510
-57,000 Reduced 5.69%
944,113 $5.5 Million
Q2 2022

Aug 15, 2022

BUY
$3.55 - $6.27 $204,835 - $361,779
57,700 Added 6.12%
1,001,113 $5.98 Million
Q1 2022

May 16, 2022

BUY
$1.9 - $5.23 $732,070 - $2.02 Million
385,300 Added 69.04%
943,413 $4.41 Million
Q4 2021

Feb 14, 2022

SELL
$1.44 - $2.86 $753,840 - $1.5 Million
-523,500 Reduced 48.4%
558,113 $1.38 Million
Q3 2021

Nov 15, 2021

SELL
$2.25 - $3.18 $203,850 - $288,108
-90,600 Reduced 7.73%
1,081,613 $3.19 Million
Q2 2021

Aug 16, 2021

BUY
$2.16 - $2.62 $1.41 Million - $1.71 Million
652,000 Added 125.33%
1,172,213 $2.93 Million
Q1 2021

May 17, 2021

BUY
$2.68 - $3.8 $1.1 Million - $1.55 Million
408,600 Added 366.09%
520,213 $1.51 Million
Q4 2020

Feb 16, 2021

SELL
$2.48 - $3.8 $273,717 - $419,406
-110,370 Reduced 49.72%
111,613 $359,000
Q3 2020

Nov 16, 2020

BUY
$1.02 - $2.15 $132,702 - $279,715
130,100 Added 141.59%
221,983 $477,000
Q2 2020

Aug 14, 2020

SELL
$0.88 - $1.32 $880 - $1,320
-1,000 Reduced 1.08%
91,883 $107,000
Q1 2020

May 15, 2020

SELL
$0.69 - $1.54 $552 - $1,232
-800 Reduced 0.85%
92,883 $85,000
Q4 2019

Feb 14, 2020

SELL
$0.72 - $1.64 $13,608 - $30,995
-18,900 Reduced 16.79%
93,683 $148,000
Q3 2019

Nov 14, 2019

SELL
$0.64 - $0.92 $384 - $552
-600 Reduced 0.53%
112,583 $94,000
Q2 2019

Aug 14, 2019

SELL
$0.8 - $1.03 $1,040 - $1,339
-1,300 Reduced 1.14%
113,183 $97,000
Q1 2019

May 15, 2019

SELL
$0.9 - $1.37 $900 - $1,370
-1,000 Reduced 0.87%
114,483 $111,000
Q4 2018

Feb 14, 2019

BUY
$0.73 - $2.19 $10,366 - $31,098
14,200 Added 14.02%
115,483 $85,000
Q3 2018

Nov 14, 2018

BUY
$1.72 - $5.24 $7,568 - $23,056
4,400 Added 4.54%
101,283 $219,000
Q2 2018

Aug 14, 2018

BUY
$3.81 - $5.26 $369,124 - $509,604
96,883 New
96,883 $482,000

About CTI BIOPHARMA CORP


  • Ticker CTIC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 114,385,000
  • Market Cap $1.04B
  • Description
  • CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients w...
More about CTIC
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.